<DOC>
	<DOCNO>NCT01734239</DOCNO>
	<brief_summary>The purpose study determine Pneumovax™ 23 ( V110 ) safe immunogenic participant Russian population 50 year age old 2 49 year age increase risk pneumococcal disease</brief_summary>
	<brief_title>A Phase III Clinical Trial Study Safety Immunogenicity Pneumovax™ 23 ( V110 ) Participants From Russian Population ( V110-018 )</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>For participant 50 year age older : underlying chronic illness must stable condition For participant 2 49 year age : participant increase risk pneumococcal disease result one following : chronic cardiovascular disease , chronic pulmonary disease , diabetes mellitus , alcoholism , chronic liver disease , cerebrospinal fluid leak , functional anatomic asplenia , sickle cell anemia , live special environment social setting crowd , close community Male , female reproductive potential , female reproductive potential agrees remain abstinent use 2 acceptable method contraception 6 week study vaccination Received prior vaccination pneumococcal vaccine Has know suspect immune dysfunction condition associate immunosuppression , receive immunosuppressive chemotherapy , include longterm systemic corticosteroid Has history autoimmune disease Received license live virus vaccine within 3 month schedule within 3 month study vaccination Received license inactivated vaccine within 28 day schedule within 28 day study vaccination Received investigational drug investigational vaccine within 2 month schedule within 28 day study vaccination ( 3 month live virus vaccine ) Received blood product immunoglobulin preparation within 6 month 28 day study vaccination Hospitalized acute illness within 3 month study vaccination Is pregnant woman nurse mother History invasive pneumococcal disease culturepositive pneumococcal disease History fever illness within 3 day study vaccination Received antibiotic therapy acute illness within 7 day study vaccination Hypersensitivity component vaccine , include phenol</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>